Instrument Inactif

Communiqués Windtree Therapeutics Inc Nasdaq

Actions

US97382D1054

Recherche biotechnologique et médicale

Communiqués

23/12	Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates	AQ
03/12	Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space	AQ
17/11	Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee	AQ
17/11	Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate	AQ
14/11	Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate	AQ
13/11	Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company	AQ
02/09/25	Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting	AQ
11/08/25	Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025	AQ
05/08/25	Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients	AQ
29/07/25	Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption	AQ
24/07/25	Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy	AQ
22/07/25	Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services	AQ
16/07/25	Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions	AQ
02/07/25	Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure	AQ
30/06/25	Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis	AQ
26/06/25	Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel	AQ
17/06/25	Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study	AQ
16/06/25	Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study	AQ
11/06/25	Windtree Receives Offer for Its Preclinical Oncology Drug Candidate	AQ
10/06/25	Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business	AQ
03/06/25	Windtree Announces Plan for Cryptocurrency Treasury Policy	AQ
22/05/25	Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025	AQ
19/05/25	Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference	AQ
16/05/25	Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates	AQ
12/05/25	Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025	AQ